Close Menu

mergers & acquisitions

Symyx also disclosed in filings with the US Securities and Exchange Commission this week that it has entered a memorandum of understanding to settle a class action suit filed by several of its shareholders regarding its impending merger agreement with Accelrys.

Symyx's board has rejected Certara's bid for the second time this week and has urged shareholders to vote in favor of a deal with Accelrys.

ExonHit said that it anticipates a lack of quorum to vote on the acquisition, which last week hit a snag on the news that Medicare may drop RedPath's pancreatic cancer test.

Symyx's board has decided that Certara's recently lowered bid is not superior to the initial agreement Symyx signed to merge with Accelrys.

The new offer, worth around $200 million, comes as Symyx prepares to finalize its previously disclosed merger with Accelrys, which values Symyx at $178 million.

The firms' merger combines technologies for pharmacogenomic testing and gene-interaction informatics.

The $7.2B deal was approved by 98 percent of shareholders who voted.

The firm has decided to focus on growing its molecular diagnostics services business rather than continuing to pursue a deal with a partner.

The proposed merger between Accelrys and Symyx may have hit a snag this week as Symyx disclosed that it will "engage in discussions" with an undisclosed firm that has made a competing offer.

Life Tech now owns 74 percent of the synthetic gene company.


New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.

A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.

Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.

In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.